What is the allergen profile of Alternaria tenuis and how should it be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Allergen Profile of Alternaria tenuis

Alternaria tenuis (now classified as Alternaria alternata) is a potent outdoor fungal allergen that represents a major risk factor for developing asthma, increasing asthma severity, and causing asthma-related fatalities, requiring aggressive environmental control and consideration for immunotherapy in sensitized patients with inadequate symptom control.

Allergen Characteristics and Clinical Significance

Alternaria species are ubiquitous fungi that produce clinically important allergens encountered primarily through inhalation of airborne spores, though hyphal fragments also carry allergenic material 1. Fungal sensitization, particularly to Alternaria species, is strongly associated with asthma development, increased disease severity, and asthma-induced deaths 1.

Key Allergen Components

The major allergen is Alt a 1, which is critical for component-resolved diagnosis 2, 3. However, Alternaria contains at least 12 recognized allergens including:

  • Alt a 1 (major allergen, function unknown)
  • Alt a 4 (disulfide isomerase)
  • Alt a 6 (enolase)
  • Alt a 8 (mannitol dehydrogenase)
  • Alt a 10 (aldehyde dehydrogenase)
  • Alt a 13 (glutathione-S-transferase)
  • Alt a MnSOD (Mn superoxide dismutase)

3

Most allergens are more abundant in nongerminating spores rather than hyphae 4, though Alt a 1 appears largely secreted into the environment at relatively low levels in both forms 4.

Environmental Distribution

Alternaria thrives during dry, windy weather (unlike hydrophilic fungi that prefer moisture) 5. Spore concentrations peak:

  • Late spring and late summer in Northern United States
  • Year-round elevation in Southern United States
  • During and after thunderstorms (spore plumes)

5

Indoor contamination occurs when spore levels exceed 1000/m³ of air or colony-forming units of 1000-10,000/m³ 1.

Management Strategy

Environmental Control (First-Line)

For outdoor exposure:

  • Remain indoors during dry, windy conditions and peak spore seasons
  • Close doors and windows; use air conditioning with outdoor vents closed
  • Avoid plant-disturbing activities (mowing, raking leaves, proximity to compost)
  • Use face masks during unavoidable outdoor activities

5

For indoor contamination:

  • Control moisture aggressively - maintain humidity below 50%
  • Seal water leaks immediately
  • Ventilate bathrooms and kitchens
  • Use dehumidifiers
  • Apply dilute bleach solution with detergent to nonporous surfaces (denatures allergens and kills mycelia)
  • Replace contaminated porous materials (wallboard) - surface treatment alone is insufficient
  • Use high-efficiency air filters
  • Maintain HVAC systems regularly; inspect for fungal contamination

1, 5

Pharmacologic Management

When environmental controls fail:

  • Intranasal corticosteroids for quality-of-life affecting symptoms 6
  • Oral second-generation antihistamines for sneezing/itching 6
  • Combination therapy if monotherapy inadequate 6

Allergen Immunotherapy

Offer or refer for immunotherapy when:

  • Symptoms inadequately controlled with medications and avoidance
  • Patient requires high medication doses or multiple medications
  • Patient experiences medication adverse effects
  • Patient prefers immunomodulation

7, 6

Critical Safety Considerations

Do NOT initiate immunotherapy if:

  • Patient is pregnant
  • Asthma is uncontrolled
  • Patient cannot tolerate injectable epinephrine

7

Before each dose, assess for uncontrolled asthma 7. Alternaria immunotherapy carries higher risk of adverse reactions (1.95% of doses) compared to other allergen extracts, with increased risk in:

  • Children
  • Patients with asthma
  • During initial treatment phase
  • Patients with higher total and specific IgE levels

8

Immunotherapy Protocols

  • Use biologically standardized extracts when available 9, 8
  • Separate Alternaria from other allergens in mixtures - proteolytic enzymes in mold extracts can digest other allergens (pollen, dust mites) 9
  • Administer only in settings equipped for anaphylaxis management
  • Observe patients for minimum 30 minutes post-injection 10
  • Continue for minimum 3 years if achieving symptomatic control 7

Diagnostic Approach

Confirm sensitization with:

  • Specific IgE testing (skin or blood) when diagnosis uncertain or empiric treatment fails 6
  • Component-resolved diagnosis using Alt a 1 for accurate identification 2, 3

Avoid repeat testing unless environmental exposures change or symptom control is lost 7.

Critical Pitfalls

  1. Standardization issues: Alternaria extracts vary widely between manufacturers in allergenic potency, protein content, and carbohydrate composition 11. Some patients test negative to one preparation but positive to others 11.

  2. Mixing incompatibility: Never combine Alternaria with pollen or animal dander extracts without separation - proteolytic activity destroys other allergens 9.

  3. Underestimating severity: Alternaria sensitization specifically correlates with severe, life-threatening asthma 12. Treat aggressively.

  4. Indoor vs outdoor sources: Address both spore infiltration AND indoor fungal growth - moisture control is non-negotiable 1, 5.

References

Guideline

environmental allergen avoidance: an overview.

Journal of Allergy and Clinical Immunology, 2001

Research

Alternaria Allergy and Immunotherapy.

International archives of allergy and immunology, 2024

Research

Going over Fungal Allergy: Alternaria alternata and Its Allergens.

Journal of fungi (Basel, Switzerland), 2023

Guideline

the diagnosis and management of rhinitis: an updated practice parameter.

Journal of Allergy and Clinical Immunology, 2008

Guideline

clinical practice guideline: allergic rhinitis.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2015

Guideline

clinical practice guideline: immunotherapy for inhalant allergy.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2024

Guideline

allergen immunotherapy: a practice parameter third update.

Journal of Allergy and Clinical Immunology, 2011

Guideline

allergen immunotherapy: a practice parameter second update.

Journal of Allergy and Clinical Immunology, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.